Heat shock proteins (HSPs) are present in all living organisms; their presence has been detected both in simple monocellular species and in highly developed vertebrates, including humans [1]. The presence of HSP-coding genes was described for the first time in 1962 [2], but the proteins themselves were discovered in 1974 in Drosophila melanogaster [3]. The name of heat-shock proteins originated from the observation that their concentration increases following exposure to thermal stress. However, it has been found that HSPs are produced in several other risky situations, such as oxidative stress, exposure to chemical agents, biological agents (viral infections) or physical agents (UV radiation), a disturbed blood supply or insufficient nutrition [4]. In such situations the proteins protect cells and promote reparative processes in the damaged proteins [5]. Therefore, HSPs are sometimes thought to be chaperone proteins, even though many of them also function as proteases, participating in eliminating the damaged proteins. Recently, increasing attention has been devoted to the role of HSPs in immune processes. In currently ongoing investigations a few HSP receptors have been identified on antigen-presenting cells (APC) and immune processes that follow their activation have been experimentally confirmed [6]. Thus, the pathway of HSP interaction
with the immune system has been demonstrated, even though the mechanism involved in the interaction still needs to be fully elucidated. HSPs are thought to represent an important element in the body’s natural defense against damage due to autoimmune mechanisms. Therefore, investigators focus on the role of HSPs both as an element of pathophysiology in immune processes and as a potential therapeutic target in autoaggressive diseases. In addition, autoaggressive diseases are not the only group of diseases in which the potential for the therapeutic application of HSPs has been considered. In oncology investigations continue on individualized vaccines directed against mutated HSPs that are typical of a given tumor [7]. This method of treatment is defined as an active specific immunotherapy using a non-cellular vaccine [8].

Another interesting theory about the way HSPs may interact with the human immune system involves the unfavorable phenomenon of molecular mimicry. This phenomenon is caused by a structural similarity between HSP molecules present in the cells of pathogenic bacteria and human HSP proteins. This may result in bacterial infection-stimulated production of anti-HSP antibodies, which leads to an autoimmune reaction. Most of the studies focused on this problem are observations of possible anti-self HSP reactivity following Mycobacterium tuberculosis (MT) and Chlamydia trachomatis (ChT) infections. ChT infection causes the formation of antibodies against ChT HSP60, but also against HSP60 of the host infected by the bacteria. These antibodies may become the cause of autoimmune reactions [9]. In MT infection, it is hypothesized that bacterial HSP70 may provoke T-lymphocyte reactivity. T-cell stimulation can be a trigger factor for autoimmune diseases such as rheumatoid arthritis or multiple sclerosis [10–12]. However, there have also been studies that rebut the theory of autoimmunity provocation by the mechanism of molecular mimicry [13].

HSPs are classified into families of differing molecular weights, which is reflected by their nomenclature, e.g. the 70 kDa protein family of is called HSP70. Proteins of a given family may fulfill various functions [5].

Inflammatory bowel diseases (IBDs) represent a group of systemic autoimmune diseases with the involvement of the alimentary tract, including ulcerative colitis, Leśniowski-Crohn’s disease, microscopic colitis and undefined colorectal inflammation. A detailed etiology of the autoimmune processes involved has not yet been determined. The treatment of IBDs continues to pose a serious medical challenge. Even though new drugs have appeared in recent years, in many patients the course of these diseases remains difficult to control, worsens the quality of life and leads finally to intestinal resection. In view of the documented chronic unfavorable effects, the surgical approach cannot be treated as the optimum therapeutic strategy; therefore numerous investigations continue to be undertaken in search of new potential pharmacological treatments.

According to recent study results, a few HSP families seem to play a significant role in the pathogenesis of inflammatory bowel diseases [14]. One of them is the HSP70 protein family. It is thought that they exhibit a potential for enhancing a specific natural defense against tissue injury due to an autoimmune mechanism. Therefore, investigations have been undertaken looking for ways to affect the activity of HSP70 proteins as a possible therapeutic strategy. In this paper, current views on role of HSP proteins in the pathophysiology and course of diseases, and in the treatment of inflammatory bowel diseases, have been reviewed.

**HSP70 in the Colorectal Mucosa of Patients with Inflammatory Bowel Diseases**

Two groups of HSP proteins with a molecular weight of 70 kDa are distinguished: HSP72 (which used to be abbreviated as HSP70), the concentration of which markedly increases in stress situations, and HSP73 (also known as HSC73, short for heat shock cognate protein), which manifests stable expression regardless of the conditions [14–16]. The decisive majority of studies on the kinetics of expression involving proteins of the HSP70 family thus pertain to HSP72. The expression of HSC73 proteins is similar in the small intestine (jejunum and ileum) and the in large intestine. HSP72, in turn, are manifested almost exclusively in the large intestine (a small degree of HSP72 expression can also be detected in the terminal fragment of the ilium – the so-called ileum terminale). HSP72 concentration is clearly the highest in the mucosa contacting the intestinal lumen, i.e. in cells of the upper portions of intestinal crypts [17].

The specific transcription factor HSF1 (heat shock factor 1) is responsible for the expression of HSP proteins. In stress situations it activates the gene coding for HSP70 proteins. In its absence (e.g., in an experimental model of mice devoid of HSF1) the expected expression of HSP70 is absent [18]. Potential HSP70 expression is also determined by genes. There is a specific genotype (HSP70-2 BB) that is associated with a better prognosis for the course of ulcerative colitis; however,
it is not related to the risk of developing the disease [19].

In inflammatory diseases HSP70 expression is significantly higher than in a healthy population. In studies performed on animals, increased expression of HSP70 proteins and HSP40 proteins was detected in the colorectal mucosa of mice with pharmacologically induced colitis. Interestingly, not all HSP families were found to undergo similar processes – the expression of HSP25, HSP32 and HSP90 remained unchanged [20]. Similar observations were found in studies involving human populations, in which increased HSP70 expression was detected in the mucosa of patients with Crohn’s disease and ulcerative colitis, as compared to the mucosa of healthy volunteers. The evaluation included not only biopsies of mucosa with macroscopically evident pathology, but also fragments described as intact in endoscopic examination: in both cases HSP70 expression was higher than in the control group [21].

High HSP70 expression is typical for the active phase of inflammatory bowel diseases, and it undergoes a decrease upon their effective treatment. In a population of patients with ulcerative colitis, HSP70 expression in the mucosa was markedly higher prior to six months of therapy with 5-ASA preparations and probiotics. This observation suggested that following remission, HSP levels in patients with inflammatory bowel diseases do not differ from those in the healthy population [22].

On the other hand, antibiotic treatment for other reason eradicates commensal bacteria and can decrease HSP70 expression. Probably some bacterial epitopes are necessarily for proper HSP70 induction [23].

Characteristic changes in HSP70 expression are observed in the epithelium of colorectal mucosa depending on the presence of the inflammatory process and on its activity (Fig. 1). In contrast, in the lamina propria the expression of HSP proteins is much lower and seems to be stable, independently of the presence of inflammatory lesions [22].

To summarize, according to recent studies, HSP70 expression in the colorectal mucosa of IBD patients depends on various mechanisms. In general, the possible increase in HSP levels is determined by genes and intestinal bacterial flora. In the active phase of ulcerative colitis HSP70 expression is higher; it is also higher in visibly inflamed mucosa than in macroscopically unchanged mucosa. When remission is achieved due to intensification of drug treatment, HSP70 expression decreases to a level close to or even equal to the level found in the healthy population.

The Role of HSP70 in the Pathological Process of Inflammatory Bowel Diseases

The presence of HSP70 proteins in augmented amounts may be a factor that inhibits the development of the inflammatory process in colorectal mucosa. This conclusion can be drawn from an experiment conducted on mice devoid of the genes that code for macrophage migration inhibitory factor. This mutation resulted in a marked augmentation of HSP70 and HSP40 in the intestinal mucosa of the experimental animals; this in turn inhibited the development of pharmacologically induced colorectal inflammation. Nevertheless, after the administration of a pharmacological factor capable of inhibiting HSP expression, the animals developed colorectal inflammation. This proved that it was just the augmented expression of HSP which protected the mice from the development of the disease process [20]. Similar conclusions can be drawn from observations of mice with hyperthermia-induced augmented expression of HSP70 and HSP90. This condition also protected the mice against pharmacologically induced colitis; animals not earlier subjected to hyperthermia developed the disease [24].

Despite the increase of HSP70 expression as a typical response to mucosa damaging factors, some basic expression of HSP70 can be detected in the colonic wall.

It is suspected that HSP70 expression is stimulated by the cells of the immune system. In an experiment conducted on mice genetically deprived of lymphocytes T and B, HSC73 expression was the same as in mice with the unmodified genome; expression of HSP70, in turn, was significantly lower in the mice devoid of the lymphocytes. Lymphocytes probably exert the detected effect through the production of cytokines, and interleukin-2 (IL-2) in particular. HSP protein induction was found
to develop under the influence of other cytokines (IL-10, IL-11, IL-1β, TNF-α), but in this case it involved mainly the HSP25 family, with no effect on HSP72 and HSC73 [17, 25]. A reciprocal relation also exists between mediators of inflammatory conditions and HSP70. In a pharmacologically induced model of colorectal inflammation, in mice with augmented HSP70 expression a significantly lower expression was observed of pro-inflammatory cytokines, such as TNF-α, IL-6, IL-1β as well as lower macrophage activity, as compared to the control group. At the same time, the course of the morbid process was much milder in the mice with augmented HSP70 expression [26]. HSP70 proteins also manifest an ability to stimulate the production of IL-10, which has been found to exert an anti-inflammatory effect in an experimental model of bacterial infection with *Listeria monocytogenes* and in experimentally induced arthritis [1].

Another variable which significantly increases expression of HSP in cells of the colorectal epithelium is the physiological bacterial flora present in the intestinal lumen. Among others, soluble particles of *Lactobacillus GG* manifest HSP70 expression stimulating activity [27]. A similar effect is exerted by *Bacteroides fragilis* strains. No such stimulation was demonstrated in the case of HSC73 molecules, the expression of which seemed to be independent of the presence of individual bacterial strains in the intestinal lumen [17]. The phenomenon of a low but detectable expression of HSP70 in the terminal fragment of the small intestine may be linked to penetration of the region by large intestinal bacterial flora: It has been proved that even the epithelium of proximal small intestine fragments reacts to contact with colonic bacterial flora by increasing HSP70 expression and by gaining the protective capacity against stress factors that is typical of the presence of these proteins [28]. A similar relationship has also been proved for pathogenic bacteria such as *Salmonella enteritidis* or *Escherichia coli* [29, 30]. A relationship between HSP70 expression and the bacterial flora of the intestinal lumen was also confirmed by the phenomenon of decreasing expression of these proteins following treatment with metronidazole (a chemotherapeutic agent particularly active against anaerobes). No such relationship could be demonstrated for ciprofloxacin, another widely-used antibiotic [17, 28].

Another probable physiological variable capable of increasing HSP70 expression is physical activity [31]. This may be one of the mechanisms by which physical exertion favorably affects the clinical course of inflammatory processes, including non-specific intestinal inflammation (Fig. 2). To date, the hypothesis has not been proved experimentally, but studies have already been published in which an increase in HSP70 expression developed in the heart and skeletal muscles as an effect of physical exertion [32, 33]. This results in a favorable, cardio-protective phenomenon [34].

### Potential Pharmacological Approaches

The evident relationship between expression of HSP70 proteins in the intestinal epithelium and a protective ability against damaging factors opens new therapeutic perspectives in intestinal diseases. In line with the observations described above, pharmacological stimulation of HSP70 expression might favorably affect the course of colorectal bowel disease or even prevent its development. Pharmacological stimulation of HSP70 expression is manifested by geranylgeranylacetone, a substance of experimentally proven ability to augment HSP70 expression in the intestinal mucosa. This ability results in a milder course or prevention against the development of chemically induced colorectal inflammation [35, 36]. Polaprezinc is another substance that stimulates HSP70 expression. This chemical compound of zinc and L-carinosine manifests anti-neoplastic and anti-oxidative properties. Administered at an appropriate time before a chemical insult to the large intestine, it can prevent the development of an inflammatory condition. At the same time, a marked increase in the expression of HSP70 is also noted [37]. In addition, the administration of quercetin (a substance that inhibits HSP70 expression) has been found to ablate the anti-inflammatory action of polaprezinc [38]. The protective action of polaprezinc has also been detected in a similar mechanism in cases of exposure of the small intestine to injury due to acetylsalicylic acid [39].
Mesalazine is one of the drugs that have been used for years in treating inflammatory bowel diseases. The substance also affects HSP70 expression, although in an indirect way. Administration of mesalazine itself fails to increase HSP70 expression in the cells of the colorectal mucosa. However, when administration of the drug is followed by exposure to hyperthermia, mesalazine potentiates the effect of high temperature, additionally increasing HSP70 expression [40]. It thus allows a better protective effect against oxidative stress to be obtained.

Glutamine administered in high doses also has exerts a protective effect in experimental large intestine inflammation. The mechanism of the protective action is probably based on increased concentrations of HSP70 and HSP25 proteins, which are observed after the substance is administered [41].

Summary

Heat shock proteins, including the HSP70 family, certainly constitute an important element in the pathophysiology of inflammatory bowel diseases. Their expression clearly increases when cell damaging factors appear, including those which accompany the inflammatory process. HSP70 proteins provide a protective effect for colorectal mucosa and therefore restrict the morbidity process. Due to the latter effect, increased HSP70 expression in the intestinal mucosa represents a potential therapeutic target which may constitute an important alternative or supplementation of current approaches to inflammatory bowel diseases.

References


Address for correspondence:

Pawel Samborski
Department of Internal Diseases, Metabolic Diseases and of Dietetics
Clinical Hospital No. 2
Poznan Medical University
Przybyszewskiego 49
60-355 Poznan
Poland
Tel.: +48 660 470 101
E-mail: samborski.pawel.mail@gmail.com

Conflict of interest: None declared

Received: 1.07.2013
Revised: 10.02.2014
Accepted: 8.05.2014